-
Laboratory studies at Kansas State University and the work of a K-State researcher are making headway in the effort to control the pandemic H1N1 virus. Juergen Richt is a Regents Distinguished Professor at K-State's College of Veterinary Medicine and is a Kansas Bioscience Authority Eminent Scholar. His work at K-State ...
-
During a meeting in Atlanta on Wednesday, a "federal advisory committee issued sweeping guidelines … for a vaccination campaign against the pandemic swine flu strain, identifying more than half the U.S. population as targets for the first round of vaccinations," CNN reports (Hellerman, 7/29)....
-
WellPoint, Inc. (NYSE: WLP) announced today that it will offer coverage for the administration of the H1N1 (swine flu) vaccine when it becomes commercially available to the general public. The vaccine administration will be covered for members whose benefit plans provide coverage for vaccines. WellPoint will also continue coverage of ...
-
As the body creates antibodies to fight invaders, a three-protein DNA repair complex called MRN is crucial for a normal gene-shuffling process to proceed properly, University of Michigan research shows. The discoveries in mice, published online this week in Nature Structural and Molecular Biology, advance understanding of the immune system ...
-
Ultraviolet (UV) radiation from sunlight may be associated with the development of certain autoimmune diseases, particularly in women, according to a study by researchers at the National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health....
-
Vaccines to protect against sexually transmitted diseases, including HIV and herpes, are being developed and may soon be available to college students. However, limited research has been conducted to determine if students will accept the vaccines once they are available. In a new study, a University of Missouri researcher has ...
-
Over 50 pharmacists have been trained to provide seasonal flu vaccinations under a private Patient Group Direction that the NPA is facilitating. Training days were conducted in London and Birmingham with further training days scheduled at the start of September 2009 in Newport, Durham, St Albans and Haydock....
-
Hoag Memorial Hospital Presbyterian announced promising data from a clinical study showing patient-specific cancer vaccines derived from patients' own cancer cells and immune cells were well tolerated and resulted in impressive long-term survival rates in patients with metastatic melanoma whose disease had been minimized by other therapies....
-
Walter and Eliza Hall Institute scientists have created a weakened strain of the malaria parasite that will be used as a live vaccine against the disease. The vaccine, developed in collaboration with researchers from the US, Japan and Canada, will be trialled in humans from early next year....
-
Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced that the company's first SynCon™ dengue virus DNA vaccine induced neutralizing antibody responses against all four distinct serotypes of dengue viruses that are transmitted to humans by mosquitoes. Currently there is no commercially available ...
-
CSL Biotherapies, a subsidiary of one of the world's leading manufacturers of thimerosal-free seasonal influenza vaccine, announced that it has begun shipment of its seasonal influenza virus vaccine to a national network of U.S. distributors for the 2009-2010 season. CSL Biotherapies plans to deliver more than eight million doses of ...
-
Schistosomiasis, one of the most important of the neglected tropical diseases, is caused by infection with parasitic helminths of the genus Schistosoma. These parasites are long lived (>10 years) and dwell within blood vessels, where they produce eggs that become the focus of intense, chronic inflammatory responses. In severe cases, ...
-
University of Rhode Island Professor Annie De Groot has been awarded a $13 million grant from the National Institutes of Health to pioneer the development and application of an integrated gene-to-vaccine program targeting emerging infectious diseases. It is the second multi-million dollar NIH grant awarded to URI researchers in recent ...
-
According to a study in a special issue of Medical Decision Making, a large-scale, covert anthrax attack on a large city would overwhelm hospital resources even with an extremely effective public health response, primarily because of expected delays in detecting the attack and initiating a response to it....
-
The Asian Strategic Alliance for Pneumococcal Disease Prevention (ASAP) is calling for the pneumonia vaccine to become an official part of India's required list of immunizations, the Times of India reports....
-
A comprehensive analysis of nearly 1,600 tumor samples has found that CT-X genes are expressed in nearly half the breast cancers that lack the estrogen receptor (ER). CT-X gene products are the targets of therapeutic cancer vaccines already in phase III clinical trials for lung cancer and melanoma. The study ...
-
Crack open the latest medical textbook to the chapter on type 2, or adult-onset, diabetes, and you'll be hard pressed to find the term "immunology" anywhere. This is because metabolic conditions and immunologic conditions are, with a few exceptions, distant cousins....
-
Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced that it has shipped the first doses of the 2009-2010 formulation of Fluzone((R)), Influenza Virus Vaccine. Fluzone vaccine is indicated for active immunization in people 6 months of age and older against influenza disease caused by ...
-
The following are stories from this week's 5th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention meeting in Cape Town, South Africa: SciDev....
-
"Global health officials are scrambling to try to prevent the spread of the H1N1 swine flu virus, with U.S. officials moving Thursday with a recommendation that the Food and Drug Administration (FDA) approve or license a [new H1N1] vaccine," without waiting on the results from "clinical trials to test its ...
